CA stock · Healthcare sector · Biotechnology
B
BELLUS Health Inc.
BLU
NASDAQ14.59
USD
-0.04
(-0.27%)
Market Closed
-21.34P/E
-12Forward P/E
-0.87P/E to S&P500
1.850BMarket CAP
- -Div Yield
Upcoming Earnings
8 Aug-14 Aug
Shares Short
5/15/23
7.15M
Short % of Float
- -
Short % of Shares Outs.
5.64%
% Held by Insiders
10.26%
% Held by Institutions
90.41%
Beta
-0.33
PEG Ratio
- -
52w. high/low
14.67/6.38
Avg. Daily Volume
4.64M
Return %
Stock
S&P 500
1 year
76.27
3.92
3 years
40.67
34.34
5 years
843.87
55.95
Scale: |
High
Low
574.56
183.60
345.60
181.44
402.83
298.08
428.76
3.25
7.58
1.08
1.48
0.83
5.99
1.30
4.37
2.13
8.12
0.61
1.30
0.69
3.50
0.94
9.39
2.64
12.03
2.01
9.84
2.60
12.69
4.98
14.67
6.38
Currency: USD
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
Revenue per share
3.71
1.27
(0.09)
1.23
1.22
0.26
(0.01)
0.16
0.22
0.09
0.01
0.00
0.00
0.00
0.00
Infinity
0.00
Earnings per share
(233.58)
(110.75)
3.59
(12.59)
3.66
(2.53)
0.11
(0.13)
0.02
(0.10)
(0.08)
(0.18)
(0.59)
(0.54)
(0.90)
(Infinity)
(0.58)
FCF per share
(168.20)
(120.81)
(19.79)
(2.20)
(2.32)
(0.34)
(0.23)
(0.22)
(0.16)
(0.13)
(0.24)
(0.22)
(0.45)
(0.51)
(0.77)
(Infinity)
(1.00)
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
4.30
2.75
0.05
- -
- -
- -
- -
- -
- -
- -
0.06
- -
- -
0.01
- -
- -
- -
Book Value per sh.
9.58
(87.27)
(14.14)
(18.70)
(15.42)
1.10
0.69
0.55
0.49
0.38
1.10
1.10
1.86
2.49
3.68
Infinity
4.03
Comm.Shares outs.
0
0
1
2
2
9
13
13
13
16
19
34
47
59
79
- -
89
Avg. annual P/E ratio
(2.7)
(4.0)
79.5
(27.5)
25.2
(1.3)
11.0
(26.9)
139.0
(24.2)
(12.8)
(10.5)
(9.6)
(12.1)
(5.2)
- -
(21.3)
P/E to S&P500
(0.2)
(0.2)
1.1
(1.3)
1.5
(0.1)
0.6
(1.5)
6.9
(1.1)
(0.5)
(0.4)
(0.4)
(0.3)
(0.2)
- -
(0.9)
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
2
1
(0)
2
3
2
(0)
2
3
1
0
0
0
0
0
0
0
Operating margin
(4,555.8)%
(7,817.6)%
18,204.3%
(610.1)%
(58.4)%
(157.4)%
2,250.9%
(103.9)%
(2.6)%
(110.8)%
(3,445.5)%
(28,302.9)%
(97,428.6)%
(219,613.3)%
(458,025.0)%
(486,768.8)%
(622,177.1)%
Depreciation (m)
2
(0)
14
1
0
(17)
1
0
0
0
0
0
1
1
0
5
8
Net profit (m)
(95)
(51)
5
(25)
9
(23)
1
(2)
0
(2)
(1)
(6)
(28)
(32)
(71)
(76)
(87)
Income tax rate
(16.9)%
(5.3)%
156.7%
(24.8)%
(152.0)%
(71.5)%
263.5%
2.4%
(7.1)%
(0.7)%
(3.4)%
9.1%
(5.4)%
0.6%
0.3%
(0.1)%
(0.1)%
Net profit margin
(6,289.4)%
(8,697.1)%
(4,019.8)%
(1,023.0)%
300.5%
(983.0)%
(1,086.8)%
(82.8)%
10.1%
(117.7)%
(1,135.8)%
(23,591.4)%
(103,777.1)%
(210,520.0)%
(445,150.0)%
(475,500.0)%
(594,633.3)%
Working capital (m)
41
(5)
8
(5)
(0)
17
13
8
6
5
19
35
86
97
241
340
318
Long-term debt (m)
35
37
17
21
40
8
5
- -
- -
- -
- -
- -
0
0
1
1
1
Equity (m)
4
(40)
(18)
(37)
(38)
10
9
7
7
6
21
37
88
147
292
391
369
ROIC
(141.1)%
(357.5)%
67.1%
(697.1)%
(75.9)%
(25.4)%
26.4%
(18.5)%
(1.1)%
(25.2)%
(22.4)%
(17.8)%
(31.2)%
(22.2)%
(25.0)%
(19.9)%
(24.4)%
Return on capital
(88.0)%
(140.7)%
(75.3)%
(69.7)%
(14.5)%
(13.3)%
(13.9)%
(14.8)%
(0.7)%
(21.9)%
(19.9)%
(18.6)%
(27.2)%
(21.5)%
(23.7)%
(19.1)%
(23.8)%
Return on equity
(2,437.2)%
126.9%
(25.4)%
67.3%
(23.7)%
(229.2)%
16.4%
(23.4)%
4.5%
(27.0)%
(7.1)%
(16.3)%
(31.5)%
(21.5)%
(24.4)%
(19.5)%
(23.5)%
Plowback ratio
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
- -
0.0%
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Capital Structure
21 Mar · 2023 | Q1
All numbers in millions
Total liabilities
$ 11
Total assets
$ 380
Long-term debt
$ 1
Cash and equiv.
$ 85
Goodwill
$ - -
Retained earnings
$ (667)
Common stock
127
Enterprise Value
$ 1,765
Working Capital
Currency: USD, in millions
2020
2021
2022
Cash & Investments
98
249
337
Receivables
1
1
2
Inventory
- -
- -
- -
Other
3
109
56
Current assets
102
258
356
Acc. Payable
1
3
5
Debt due
0
0
0
Other
5
14
11
Current liabilities
6
17
16
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
- -
(8.27)%
(200.60)%
Cash flow
25.94%
88.91%
55.75%
Earnings
6.82%
126.15%
(21.95)%
Dividends
- -
- -
- -
Book value
33.89%
84.18%
68.70%
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2021
0
0
0
0
0
2022
0
0
0
0
0
2023
0
- -
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2021
(0.20)
(0.22)
(0.29)
(0.17)
(0.88)
2022
(Infinity)
(Infinity)
(Infinity)
(Infinity)
(Infinity)
2023
(0.20)
- -
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Biotechnology
CEO:
Mr. Roberto Francesco Bellini
Full-time employees:
74
City:
Laval
Address:
275 Armand-Frappier Boulevard
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.